Immunotherapy of Malignant Tumors Using Antisense Anti-IGF-I Approach: Case of Glioblastoma

DOI: 10.4236/jct.2014.57078   PDF   HTML   XML   3,296 Downloads   4,401 Views   Citations


The review article describes the criteria established for methodology of antisense anti IGF-I therapy of malignant tumors, particularly of glioblastoma. The cancer patients, after classical therapy of surgery, radiotherapy and chemotherapy, have undergone the injection of genetically modified autologous malignant cells—transfected by IGF-I antisense/triple helix expression vectors. For all cancer patients supervised for up to 19 months, the period corresponding to minimum survival of glioblastoma patients, the following common immune criteria for “anti IGF-I” strategy were admitted: 1) characteristics of cell “vaccines”—absence of IGF-I and expression of MHC-I in cloned transfected cells; 2) the peripheral blood lymphocytes, PBL cells, removed after every of two successive vaccinations, demonstrate an increasing level of CD8+ and CD8+28+ molecules (with a switch from CD8+11b+ to CD8+11b-).

Share and Cite:

Trojan, A. , Jay, L. , Kasprzak, H. , Anthony, D. and Trojan, J. (2014) Immunotherapy of Malignant Tumors Using Antisense Anti-IGF-I Approach: Case of Glioblastoma. Journal of Cancer Therapy, 5, 685-705. doi: 10.4236/jct.2014.57078.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Catuogno, S., Esposito, C.L., Quintavalle, C., Condorelli, G., de Franciscis, V. and Cerchia, L. (2012) Nucleic Acids in Human Glioma Treatment: Innovative Approaches and Recent Results. Journal of Signal Transduction, 2012, Article ID: 735135.
[2] Caruso, G. and Caffo, M. (2014) Antisense Oligonucleotides in the Treatment of Cerebral Gliomas Review of Concerning Patents. Recent Patents on CNS Drug Discovery. 2212-3954
[3] Trojan, J., Johnson, T.R., Rudin, S.D., Ilan, J., Tykocinski, M.L. and Ilan, J. (1993) Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA. Science, 259, 94-99.
[4] Rubenstein, J.L., Nicolas, J.F. and Jacob, F. (1984) L’ARN non sens (nsARN): Un outil pour inactiver spécifique mentl’expression d’un gène donné in Vivo [Nonsense RNA: A Tool for Specifically Inhibiting the Expression of a Gene in Vivo]. Comptes Rendus Academie des Sciences Paris, 299, 271-274.
[5] Derwan, P. (1992) Reagents for the Site-Specific Cleavage of Megabase DNA. Nature, 359, 87-88.
[6] Helene, C. (1994) Control of Oncogene Expression by Antisense Nucleic Acids. European Journal of Cancer, 30, 1721-1726.
[7] Trojan, J., Cloix, J.F., Ardourel, M.Y., Chatel, M. and Anthony, D. (2007) Insulin-Like Growth Factor Type I Biology and Targeting in Malignant Gliomas. Neuroscience, 145, 795-812.
[8] Ellouk-Achard, S., Djenabi, S., De Oliveira, G.A., Dessay, G., Duc, H.T., Zoar, M., Trojan, J., Claude, J.R., Sarasin, A. and Lafarge-Frayssinet, C. (1998) Induction of Apoptosis in Rat Hepatocarcinoma Cells by Expression of IGF-I Antisense c-DNA. Journal of Hepatology, 29, 807-818.
[9] Trabado, S., Van Binh, P.N., Martin, C., Lafarge-Frayssinet, C., Lone, Y.C., Trojan, J., Warnet, J.M. and Duc, H.T. (2007) Stimulation of Anti-Melanoma Immune Effectors via Modified Tumour Cells Exhibiting Inhibited IGF-I and Low CD9. Biomedicine & Pharmacotherapy, 61, 494-498.
[10] Pan, Y., Trojan, J., Guo, Y. and Anthony, D.D. (2013) Rescue of MHC-1 Antigen Processing Machinery by DownRegulation in Expression of IGF-I in Human Glioblastoma Cells. PLoS ONE, 8, Article ID: e58428.
[11] Andrews, D.W., Resnicoff, M., Flanders, A.E., Kenyon, L., Curtis, M., Merli, G., Baserga, R., Iliakis, G. and Aiken, R.D. (2001) Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas. Journal of Clinical Oncology, 19, 2189-2200.
[12] Djavan, W., Aldert, M., Seitz, C. and Marberger, M. (2001) Insulin-Like Growth Factors and Prostate Cancer. World Journal of Urology, 19, 225-233.
[13] Pollak, M.N., Schernhammer, E.S. and Hankinson, S.E. (2004) Insulin-Like Growth Factors and Neoplasia. Nature Review Cancer, 4, 505-518.
[14] Baserga, R. (2005) The Insulin-Like Growth Factor-I Receptor as a Target for Cancer Therapy. Expert Opinion on Therapeutic Targets, 9, 753-768.
[15] Brooks, W.H., Latta, R.B., Mahaley, M.S., Roszman, T.L., Dudka, L. and Skaggs, C. (1981) Immunobiology of Primary Intracranial Tumors. Part 5: Correlation of a Lymphocyte Index and Clinical Status. Journal of Neurosurgery, 54, 331-337.
[16] Blanchet, O., Bourge, J.F., Zinszner, H., Israel, A., Kourilsky, P., Dausset, J., Degos, L. and Paul, P. (1992) Altered Binding of Regulatory Factors to HLA Class I Enhancer Sequence in Human Tumor Cell Lines Lacking Class I Antigen Expression. Proceedings of the National Academy of Science of the United States of America, 89, 3488-3492.
[17] Saji, M., Moriarty, J., Ban, T., Singer, D. and Kohn, L. (1992) Major Histocompatibility Complex Class I Gene Expression in Rat Thyroid Cells Is Regulated by Hormones, Methimazole and Iodide as Well as Interferon. Journal of Clinical Endocrinology and Metabolism, 75, 871-878.
[18] Schwartz, R.H. (1992) Costimulation of T Lymphocytes: The Role of CD28, CTLA-4 and B7/BBI in Interleukin-2 Production and Immunotherapy. Cell, 71, 1065-1068.
[19] Wu, A., Wiesner, S., Xiao, J., Ericson, K., Chen, W., Hall, W.A., Low, W.C. and Ohlfest, J.R. (2007) Expression of MHC-I and NK Ligands on Human CD133+ Gliomacells: Possible Targets of Immunotherapy. Journal of Neuro-Oncology, 83, 121-131.
[20] Trojan, J., Duc, H.T., Upegui-Gonzalez, L., Hor, F., Guo, Y., Anthony, D.D. and Ilan, J. (1996) Presence of MHCI and B-7 Molecules in Rat and Human Glioma Cells Expressing Antisense IGF-I mRNA. Neuroscience Letters, 212, 9-12.
[21] Trojan, J., Johnson, T., Rudin, S., Blossey, B., Kelley, K., Shevelev, A., Abdul-Karim, F., Anthony, D., Tykocinski, M., Ilan, J. and Ilan, J. (1994) Gene Therapy of Murine Teratocarcinoma: Separate Functions for Insulin-Like Growth Factors I and II in Immunogenicity and Differentiation. Proceedings of the National Academy of Science of the United States of America, 91, 6088-6092.
[22] Lasfarge-Frayssinet, C., Duc, H.T., Frayssinet, C., Sarasin, A., Anthony, D.D., Guo, Y. and Trojan, J. (1997) Antisense Insulin-Like Growth Factor I Transferred into a Rat Hepatoma Cell Line Inhibits Tumorigenesis by Modulating Major Histocompatibility Complex I Cell Surface Expression. Cancer Gene Therapy, 4, 276-285.
[23] Upegui-Gonzalez, L.C., Ly, A., Sierzega, M., Jarocki, P., Trojan, L.A., Duc, H.T., Pan, Y., Shevelev, A., Henin, D., Anthony, D.D., Nowak, W., Popiela, T. and Trojan, J. (2001) IGF-I Triple Helix Strategy in Hepatoma Treatement. Hepato-Gastroenterology, 48, 656-662.
[24] Ly, A., Duc, H.T., Kalamarides, M., Trojan, L.A., Pan, Y., Shevelev, A., Fran?ois, J.-C., Noel, T., Kane, A., Henin, D., Anthony, D.D. and Trojan, J. (2001) Human Glioma Cells Transformed by IGF-I Triple-Helix Technology Show Immune and Apoptotic Characteristics Determining Cell Selection for Gene Therapy of Glioblastoma. Molecular Pathology, 54, 230-239.
[25] Weintraub, H., Izant, J.G. and Harland, R.M. (1985) Antisense RNA as a Molecular Tool for Genetic Analysis. Trends in Genetics, 1, 23-25.
[26] Green, P.J., Pines, O. and Inouye, M. (1986) The Role of Antisense RNA in Gene Regulation. Annual Review of Biochemistry, 55, 569-597.
[27] Merino, E., Balbas, P., Puente, J.L. and Bolivar F. (1994) Antisense Overlapping Open Reading Frames in Genes from Bacteria to Humans. Nucleic Acids Research, 22, 1903-1908.
[28] Dias, N. and Stein, C.A. (2002) Antisense Oligonucleotides: Basic Concepts and Mechanisms. Molecular Cancer Therapeutics, 1, 347-355.
[29] Galderisi, U., Cascino, A. and Giordano, A. (1999) Antisense Oligonucleotides as Therapeutic Agents. Journal of Cellular Physiology, 181, 251-257.<251::AID-JCP7>3.0.CO;2-D
[30] Bennett, C.F., Butler, M., Cook, P.D., Geary, R.S., Levin, A.A., Mehta, R., Teng, C.L., Desmukh, H., Tillman, L. and Hardee, G. (2000) Antisense Oligonucleotides—Based Therapeutics. In: Templeton, N.S. and Lasic D.D., Eds., Gene Therapy, Marcel Dekker, New York, 305-332.
[31] Tsai, Y.J., Hu, C.C., Chu, C.C. and Imae, T. (2011) Intrinsically Fluorescent PAMAM Dendrimer as Gene Carrier and Nanoprobe for Nucleic Acids Delivery: Bioimaging and Transfection Study. Biomacromolecules, 12, 4283-4290.
[32] Scaggiante, B., Morassutti, C., Tolazzi, G., Michelutti, A., Baccarani, M. and Quadrifoglio, E. (1994) Effect of Unmodified Triple Helix-Forming Oligodeoxyribonucleotide Targeted to Human Multidrug-Resistance Gene mdr1 in MDR Cancer Cells. FEBS Letters, 352, 380-384.
[33] Thomas, T., Faaland, C., Gallo, M. and Thomas, I. (1995) Suppression of c-myc Oncogene Expression by a Polyamine-Complexed Triplex Forming Oligonucleotide in MCF-7 Breast Cancer Cells. Nucleic Acids Research, 23, 3594-3599.
[34] Vasquez, K.M. and Wilson, I.H. (1998) Triplex-Directed Modification of Genes and Gene Activity. Trends in Biochemical Science, 23, 4-9.
[35] Mayfield, C., Ebbinghaus, S., Gee, I., Jones, D., Rodu, B., Squibb, M. and Miller, D. (1994) Triplex Formation by the Human Haras Promoter Inhibits Spl Binding and in Vitro Transcription. Journal of Biological Chemistry, 69, 18232-18238.
[36] Rininsland, F., Johnson, T.R., Chernicky, C.L., Schulze, E., Burfeind, P. and Ilan, J. (1997) Suppression of InsulinLike Growth Factor Type I Receptor by a Triple-Helix Strategy Inhibits IGF-I Transcription and Tumorigenic Potential of Rat C6 Glioblastoma Cells. Proceedings of the National Academy of Science of the United States of America, 94, 5854-5859.
[37] Shevelev, A., Burfeind, P., Schulze, E., Rininsland, F., Johnson, T., Trojan, J., Chernicky, C., Hélène, C., Ilan, J. and Ilan, J. (1997) Potential Triple Helix-Mediated Inhibition of IGF-I Gene Expression Significantly Reduces Tumorigenicity of Glioblastoma in an Animal Model. Cancer Gene Therapy, 4, 105-112.
[38] Aggarwal, B., Schwarz, L., Hogan, M. and Rando, R. (1996) Triple Helix-Forming Oligodeoxyribonucleotides Targeted to the Human Tumor Necrosis Factor (TNF) Gene Inhibit TNF Production and Block the TNF Dependent Growth of Human Glioblastoma Tumor Cells. Cancer Research, 56, 5156-5164.
[39] Sia, K.C., Chong, W.K., Ho, I.A., Yulyana, Y., Endaya, B., Huynh, H. and Lam, P.Y. (2010) Hybrid Herpes Simplex Virus/Epstein-Barr Virus Amplicon Viral Vectors Confer Enhanced Transgene Expression in Primary Human Tumors and Human Bone-Marrow-Derived Mesenchymal Stem Cells. The Journal of Gene Medicine, 12, 848-858.
[40] Trojan, L.A., Kopinski, P., Mazurek, A., Chyczewski, L., Ly, A., Jarocki, P., Niklinski, J., Shevelev, A., Trzos, R., Pan, Y., Gitis, D.J., Bierwagen, M., Czapiewska, J.L., Wei, M.X., Michalkiewicz, J., Henin, D., Popiela, T., Evrard, F., Kasprzak, H., Anthony, D.D. and Trojan, J. (2003) IGF-I Triple Helix Gene Therapy of Rat and Human Gliomas. Annales Academiae Medicae Bialostocensis (Roc Akad Med Bial), 48, 18-27.
[41] Popiela, T., Sierzega, M., Gach, T., Jarocki, P. and Trojan, J. (2003) Phase I Trial of Colorectal Cancer Immune Therapy Using Autologous Cancer Cells Transfected with an IGF-I Antisense Plasmid [Abstract]. Acta Chirurgica Belgica, 5, 2-3.
[42] Trojan, L.A., Ly, A., Kopinski, P., Ardourel, M.Y., Dufour, T., Duc, H.T., Kasprzak, H., Cloix, J.F., Wei, M.X., Chyczewski, L., Pan, Y., Chatel, M., Anthony, D.D. and Trojan, J. (2006) Antisense and Triple Helix Anti IGF-I Tumours Vaccines—Gene Therapy of Gliomas. International Journal of Cancer Research and Prevention, 2, 227-243.
[43] Trojan, L.A., Ly, A., Upegui-Gonzalez, L., Jarocki, P., Shevelev, A., Sierzega, M., Wei, M.X., Lafarge-Frayssinet, C., Kopinski, P., Pan, Y.J., Kulig, J., Anthony, D., Popiela, T., Duc, H.T. and Trojan, J. (2009) Antisense Anti IGF-I Therapy of Primary Hepatic Cancer. African Journal of Cancer, 1, 21-30. Cancer
[44] Matlib, M.A., Kihara, M., Farrell, C. and Dage, R.C. (1988) The Na+-Ca2+ Exchange System in Vascular Smooth Muscle Cell Membrane Vesicles Isolated from Cultured Cells and from Tissue Is Similar. Biochemical and Biophysical Acta (BBA), Biomembranes, 939, 173-177.
[45] Frankenberger, B., Pohla, H., Noessner, E., Willimsky, G., Papier, B., Pezzutto, A., Kopp, J., Oberneder, R., Blank enstein, T. and Schendel, D.J. (2005) Influence of CD80, Interleukin-2, and Interleukin-7 Expression in Human Renal Cell Carcinoma on the Expansion, Function, and Survival of Tumor-Specific CTLs. Clinical Cancer Research, 11, 1733-1742.
[46] Naoyuki, T., Takayoshi, M. and Yoshikatsu, E. (2005) Human Monocyte-Derived Dendritic Cells Pulsed with WildType p53 Protein Efficiently Induce CTLs against p53 Overexpressing Human Cancer Cells. Clinical Cancer Research, 11, 1312-1318.
[47] Patel, S., Doble, B. and Woodgett, J.R. (2004) Glycogen Synthase Kinase-3 in Insulin and Wnt Signalling: A DoubleEdged Sword? Biochemical Society Transactions, 32, 803-808.
[48] Beckner, M.E., Gobbel, G.T., Abounader, R., Burovic, F., Agostino, N.R., Laterra, J. and Pollack, I.F. (2005) Glycolytic Glioma Cells with Active Glycogen Synthase Are Sensitive to PTEN and Inhibitors of PI3K and Gluconeo Genesis. Laboratory Investigation, 85, 1457-1470.
[49] Premkumar, D.R., Arnold, B., Jane, E.P. and Pollack, I.F. (2006) Synergistic Interaction between 17-AAG and Phosphatidylinositol 3-Kinase Inhibition in Human Malignant Glioma Cells. Molecular Carcinogenesis, 45, 47-59.
[50] Ardourel, M.Y., Blin, M., Moret, J.L., Dufour, T., Duc, H.T., Hevor, T., Trojan, J. and Cloix, J.F. (2007) A New Putative Target for Antisense Gene Therapy of Glioma: Glycogen Synthetase. Cancer Biology and Therapy, 6, 719-723.
[51] Trojan, J., Ly, A., Wei, M.X., Kopinski, P., Ardourel, M.Y., Pan, Y., Trojan, L.A., Dufour, D., Shevelev, A., Andres, C., Chatel, M., Kasprzak, H., Anthony, D.D. and Duc, H.T. (2010) Antisense Anti-IGF-I Cellular Therapy of Malignant Tumours: Immune Response in Cancer Patients. Biomedicine & Pharmacotherapy, 64, 576-578.
[52] Harding, F.A., McArthur, J.G., Gross, J.A., Raulet, D.H. and Allison, J.P. (1992) CD28-Mediated Signalling Co-Stimulates Murine T Cells and Prevents Induction of Anergy in T-Cell Clones. Nature, 356, 607-609.
[53] Di Tomaso, T., Mazzoleni, S., Wang, E., Sovena, G., Clavenna, D., Franzin, A., Mortini, P., Ferrone, S., Doglioni, C., Marincola, F.M., Galli, R., Parmiani, G. and Maccalli, C. (2010) Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients. Clinical Cancer Research, 16, 800-813.
[54] Migliorini, D., Dietrich, P.Y. and Walker, P.R. (2013) Maximizing Output from Current Glioma Vaccine Trials to Construct Robust Next Generation Immunotherapies. Immunotherapy, 5, 1147-1150.
[55] Fakhrai, H., Dorigo, O., Shawler, D.L., Lin, H., Mercola, D., Black, K.L., Royston, Y. and Sobol, R.E. (1996) Eradication of Established Intracranial Rat Gliomas by Transforming Growth Factor Beta Antisense Gene Therapy. Proceedings of the National Academy of Science of the United States of America, 93, 2909-2914.
[56] Schlingensiepen, K.H., Schlingensiepen, R., Steinbrecher, A., Hau, P., Bogdahn, U., Fischer-Blass, B. and Jachimczak, P. (2006) Targeted Tumor Therapy with the TGF-Beta2 Antisense Compound AP 12009. Cytokine Growth Factor Review, 17, 129-139.
[57] Schlingensiepen, K.H., Fischer-Blass, B., Schmaus, S. and Ludwig, S. (2008) Antisense Therapeutics for Tumor Treatment: The TGF-Beta2 Inhibitor AP 12009 in Clinical Development against Malignant Tumors. Recent Results Cancer Research, 177, 137-150.
[58] Hau, P., Jachimczak, P. and Bogdahn, U. (2009) Treatment of Malignant Gliomas with TGF-Beta2 Antisense Oligonucleotides. Expert Review of Anticancer Therapy, 9, 1663-1674.
[59] Hau, P., Jachimczak, P., Schlaier, J. and Bogdahn, U. (2011) TGF-β2 Signaling in High-Grade Gliomas. Current Pharmaceutical Biotechnology, 12, 2150-2157.;i3597
[60] Anthony, D.D. (1997) Ex Vivo and in Vivo IGF-1 Antisense RNA Strategies for Treatment of Cancers in Humans. Cancer Gene Therapy, 2, 322.
[61] Matthew, L., Saiter, B. and Bhardwag, N. (1998) Dendritic Cells Acquire Antigen from Apoptotic Cells and Induce Class I-Restricted CTLs. Nature, 392, 86-89.
[62] Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F. and Vescovi, A. (2004) Isolation and Characterization of Tumorigenic, Stem-Like Neural Precursors from Human Glioblastoma. Cancer Research, 64, 7011-7021.
[63] Tunici, P., Bissola, E., Lualdi, E., Pollo, B., Cajola, L., Broggi, G., Sozzi, G. and Finocchiaro, G. (2004) Genetic Alterations and in Vivo Tumorigenicity of Neurospheres Derived from an Adult Glioblastoma. Molecular Cancer, 6, 3-25.
[64] Downward, J. (2003) Targeting RAS Signalling Pathways in Cancer Therapy. Nature Review Cancer, 3, 11-22.
[65] Lo, H.W. (2010) Targeting Ras-RAF-ERK and Its Interactive Pathways as a Novel Therapy for Malignant Gliomas. Current Cancer Drug Targets, 10, 840-848.
[66] Goudar, R.K., Shi, Q., Hjelmeland, M.D., Keir, S.T., McLendon, R.E., Wikstrand, C.J., Reese, E.D., Conrad, C.A., Traxler, P., Lane, H.A., Reardon, D.A., Cavenee, W.K., Wan, X.F., Bigner, D.D., Friedman, H.S. and Rich, J.N. (2005) Combination Therapy of Inhibitors of Epidermal Growth Factor Receptor/Vascular Endothelial Growth Factor Receptor 2 (AEE788) and the Mammalian Target of Rapamycin (RAD001) Offers Improved Glioblastoma Tumor Growth Inhibition. Molecular Cancer Therapeutics, 4, 101-112.
[67] Kindt, T.J., Goldsby, R.A. and Osborne, B.A. (2007) Kuby Immunology. W. H. Freeman and Co., New York.
[68] Lankat-Buttgereit, B. and Tampé, R. (1999) The Transporter Associated with Antigen Processing TAP: Structure and Function. FEBS Letters, 464, 108-112.
[69] Groettrup, M., van den Broek, M., Schwartz, K., Macagno, A., Khan, S., de Giuli, R. and Schmidtke, G. (2001) Structural Plasticity of the Proteasome and Its Function in Antigen Processing. Critical Reviews in Immunology, 21, 339-358.
[70] Niedermann, G. (2002) Immunological Functions of the Proteasome. Current Topics in Microbiology and Immunology, 268, 91-136.
[71] Rodríguez, J.A., Galeano, L., Palacios, D.M., Gómez, C., Serrano, M.L., Bravo, M.M. and Combita, A.L. (2012) Altered HLA Class I and HLA-G Expression Is Associated with IL-10 Expression in Patients with Cervical Cancer. Pathobiology, 79, 72-83.
[72] Stupp, R., Hegi, M. and Weller, M. (2010) Neuro-Oncology, a Decade of Temozolomide and beyond. Expert Review of Anticancer Therapy, 10, 1675-1677.
[73] Wen, P.Y., Yung, W.K., Lamborn, K.R., Dahia, P.L., Wang, Y., Peng, B., Abrey, L.E., Raizer, J., Cloughesy, T.F., Fink, K., Gilbert, M., Chang, S., Junck, L., Schiff, D., Lieberman, F., Fine, H.A. and Prados, M.D. (2006) Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08. Clinical Cancer Research, 12, 4899-4907.
[74] Pan, Q., Chanthery, Y., Liang, W.C., Stawicki, S., Mak, J., Rathore, N., et al. (2007) Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth. Cancer Cell, 11, 53-67.
[75] Piwecka, M., Rolle, K., Wyszko, E., Zukiel, R., Nowak, S., Barciszewska, M.Z. and Barciszewski, J. (2011) Nucleic Acid-Based Technologies in Therapy of Malignant Gliomas. Current Pharmaceutical Biotechnology, 12, 1805-1822.
[76] Kjaergaard, J., Wang, L.X., Kuriyama, H., Shu, S. and Plautz, G.E. (2005) Active Immunotherapy for Advanced in Tracranialmurine Tumors by Using Dendritic Cell-Tumor Cell Fusion Vaccines. Journal of Neurosurgery, 103, 156-164.
[77] Reardon, D.A., Quinn, J.A., Vredenburgh, J.J., Gururangan, S., Friedman, A.H., Desjardins, A., Sathornsumetee, S., Herndon II, J.E., Dowell, J.M., McLendon, R.E., Provenzale, J.M., Sampson, J.H., Smith, R.P., Swaisland, A.J., Ochs, J.S., Lyons, P., Tourt-Uhlig, S., Bigner, D.D., Friedman, H.S. and Rich, J.N. (2006) Phase 1 Trial of Gefitinib plus Sirolimus in Adults with Recurrent Malignant Glioma. Clinical Cancer Research, 12, 860-868.
[78] Cavazzana-Calvo, M., Hacein-Bey-Abina, S. and Fischer, A. (2010) Ten Years of Gene Therapy: Thoughts and Perspectives. Medecine Science (Paris), 26, 115-118.
[79] Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., Kros, J.M., Hainfellner, J.A., Mason, W., Mariani, L., Bromberg, J.E., Hau, P., Mirimanoff, R.O., Cairncross, J.G., Janzer, R.C. and Stupp, R. (2005) MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. The New England Journal of Medicine, 352, 997-1003.
[80] Gorlia, T., van den Bent, M.J., Hegi, M.E., Mirimanoff, R.O., Weller, M., Cairncross, J.G., Eisenhauer, E., Belanger, K., Brandes, A.A., Allgeier, A., Lacombe, D. and Stupp, R. (2008) Nomograms for Predicting Survival of Patients with Newly Diagnosed Glioblastoma: Prognostic Factor Analysis of EORTC and NCIC Trial 26981-22981/CE.3. The Lancet Oncology, 9, 29-38.
[81] Stupp, R. and Hottinger, A.F. (2008) Management of Malignant Glioma—Quo Vadis? Onkologie, 31, 300-302.
[82] Fakhrai, H., Mantil, J.C., Liu, L., Nicholson, G.L., Murphy-Satter, C.S., Ruppert, J. and Shawler, D.L. (2006) Phase I Clinical Trial of a T5GF-Beta Antisense-Modified Tumor Cell Vaccine in Patients with Advanced Glioma. Cancer Gene Therapy, 13, 1052-1060.
[83] Abele, R. and Tampe, R. (2006) Modulation of the Antigen Transport Machinery TAP by Friends and Enemies. FEBS Letters, 580, 1156-1163.
[84] Townsend, S.E. and Allison, J.A. (1993) Tumor Rejection after Direct Costimulation of CD8+ T Cells by Transfected Melanoma Cells. Science, 259, 368-370.
[85] Labropoulos, S.V. and Razis, E.D. (2007) Imatinib in the Treatment of Dermatofibrosarcoma Protuberans. Biologics, 1, 347-353.
[86] Benimetskaya, L. and Stein, C.A. (2002) Antisense Therapy: Recent Advances and Relevance to Prostate Cancer. Clinical Prostate Cancer, 1, 20-30.
[87] Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K. and Pehamberger, H. (2000) Chemosensitization of Malignant Melanoma by BCL2 Antisense Therapy. The Lancet, 356, 1728-1733.
[88] Zangemeister-Wittke, U. (2003) Antisense to Apoptosis Inhibitors Facilitates Chemotherapy and TRAIL-Induced Death Signaling. Annals of the New York Academy of Science, 1002, 90-94.
[89] Tang, J., Flomenberg, P., Harshyne, L., Kenyon, L. and Andrews, D.W. (2005) Glioblastoma Patients Exhibit Circulating Tumor-Specific CD8+ T Cells. Clinical Cancer Research, 11, 5292-5299.
[90] Rincon, O.L., Pareja, L.R., Jaramillo, S. and Aristizabal, B.H. (2007) Human Papillomavirus, Immune Response and Cervical Cancer: A Complex Relationship. Review Colombian of Obstetric and Ginecology, 58, 58-68.
[91] Lemoine, F.M., Cherai, M., Giverne, C., Dimitri, D., Rosenzwajg, M., Trebeden-Negre, H., Chaput, N., Barro, B., Thioun, N., Gattegnio, B., Selles, F., Six, A., Azar, N., Lotz, J.P., Buzyn, A., Sibony, M., Delcourt, A., Boyer, O., Herson, S., Klatzmann, D. and Lacave, R. (2009) Massive Expansion of Regulatory T-Cells Following Interleukin 2 Treatment during a Phase I-II Dendritic Cell-Based Immunotherapy of Metastatic Renal Cancer. International Journal of Oncology, 235, 569-581.
[92] Chappert, P., Leboeuf, M., Rameau, P., Lalfer, M., Desbois, S., Liblau, R.S., Danos, O., Davoust, J.M. and Gross, D.A. (2010) Antigen-Specifictreg Impair CD8+ T-Cell Priming by Blocking Early T-Cell Expansion. European Journal of Immunology, 40, 339-350.
[93] Le Gall, T., Loizeau, D., Picquet, E., Carmoy, N., Yaouanc, J.J., Burel-Deschamps, L., Delépine, P., Giamarchi, P., Jaffrès, P.A, Lehn, P. and Montier, T. (2010) A Novel Cationic Lipophosphoramide with Diunsaturated Lipid Chain Synthesis, Physicochemical Properties and Transfection Activities. Journal of Medicinal Chemistry, 53, 1496-1508.
[94] Engelen, S., Trojan, L.A., Sacquin-Mora, S., Lavery, R. and Carbone, A. (2009) Joint Evolutionary Trees: A LargeScale Method to Predict Protein Interface Based on Sequence Sampling. PLoS Computational Biology, 5, Article ID: e1000267.
[95] Mack, J.T., Brown, C.B. and Tew, K.D. (2008) ABCA2 as a Therapeutic Target in Cancer and Nervous System Disorders. Expert Opinion on Therapeutic Targets, 12, 491-450.
[96] Trojan, L.A., Wei, M.X., Jarocki, P., Glogowska, A., Ly, A., Czarny, J., Kopinski, P., Przewlocki, R., Henin, D. and Trojan, J. (2002) IGF-I: From Diagnostic to Triple-Helix Gene Therapy of Glioblastom. Acta Biochimica Polonica, 49, 979-990.
[97] Adachi, Y., Yamamoto, H., Ohashi, H., Endo, T., Carbone, D.P., Imai, K. and Shinomura, Y. (2010) A Candidate Targeting Molecule of Insulin-Like Growth Factor-I Receptor for Gastrointestinal Cancers. World Journal of Gastroenterology, 16, 5779-5789.
[98] Moro-Sibilot, D.M., Coudurier, M. and Lantuejou, S. (2010) Targeting Insulin-Like Growth Factors in the Treatment of Cancer. Review des Maladies Respiratoires, 27, 959-963.
[99] Sachdev, D. (2010) Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy. Current Drug Targets, 11, 1121-1132.
[100] Zumkeller, W. (2002) IGFs and IGF-Binding Proteins as Diagnostic Markers and Biological Modulators in Brain Tumours. Experimental Review of Molecular Diagnostic, 2, 473-477.
[101] Wu, Y., Yakar, S., Henninghausen, L. and Le Roith, D. (2002) Circulating Insulin-Like Growth Factor-I Levels Regulatecolon Cancer Growth and Metastasis. Cancer Research, 62, 1030-1035.
[102] Dietrich, P.Y., Dutoit, V., Tran Thang, N.N. and Walker, P.R. (2010) T-Cell Immunotherapy for Malignant Glioma: Toward a Combined Approach. Current Opinion in Oncology, 22, 604-610.
[103] Iwami, K., Natsume, A. and Wakabayashi, T. (2010) Gene Therapy for High-Grade Glioma. Neurologia Medico, Chirurgica (Tokyo), 50, 727-736.
[104] Le Corre, S.S., Berchel, M., Belmadi, N., Denis, C., Haelters, J.P., Le Gall, T., Lehn, P., Montier, T. and Jaffrès, P.A. (2014) Cationic Lipophosforamidates with Two Different Lipid Chains: Synthesis and Evaluation as Gene Carriers. Organic & Biomolecular Chemistry, 12, 1463-1474.!recentarticles&all

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.